EDM Platform for Genetic Medicine
Cancer
Key Facts
About Coastar Therapeutics
Coastar Therapeutics is developing a novel biological payload delivery platform to overcome key challenges in genetic medicine, specifically immune clearance and lack of targeting. The company's core technology leverages engineered red blood cell membranes to create a stealthy, targeted delivery vehicle for a range of genetic payloads. Coastar is actively engaging with global partners and has gained recognition as an innovative startup, evidenced by its selection as a 2025 'Cool Company' and participation in major industry conferences like BIOCOM 2026.
View full company profileAbout Coastar Therapeutics
Coastar Therapeutics is developing a novel biological payload delivery platform to overcome key challenges in genetic medicine, specifically immune clearance and lack of targeting. The company's core technology leverages engineered red blood cell membranes to create a stealthy, targeted delivery vehicle for a range of genetic payloads. Coastar is actively engaging with global partners and has gained recognition as an innovative startup, evidenced by its selection as a 2025 'Cool Company' and participation in major industry conferences like BIOCOM 2026.
View full company profileTherapeutic Areas
Other Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Shared Antigen mRNA Cancer Vaccines | BioNTech | Phase 2 |
| Targeted Oncology Therapies | BioNTech | Phase 1/2 |
| ARGX-119 | Argenx | Phase 1 |
| Oncology Program | Shionogi | Clinical |
| Bmab (Bevacizumab) | Biocon | Approved |
| Ciforadenant (CPI-444) | Corvus Pharmaceuticals | Phase 1/2 |
| Mupadolimab (CPI-006) | Corvus Pharmaceuticals | Phase 1 |
| tovecimig | Compass Therapeutics | Clinical |
| CTX-8371 | Compass Therapeutics | Clinical |
| XmAb 14045 | Xencor | Clinical |
| XmAb 13676 | Xencor | Clinical |
| Vibostolimab | Xencor | Clinical |